Effect of anti–tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis—A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic. / Syed, Maha N.; Shah, Mohsin; Shin, Daniel B.; Wan, Marilyn T.; Winthrop, Kevin L.; Gelfand, Joel M.In: Journal of the American Academy of Dermatology, Vol. 84, No. 1, 01.2021, p. 161-163.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Effect of anti–tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis—A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic
AU - Syed, Maha N.
AU - Shah, Mohsin
AU - Shin, Daniel B.
AU - Wan, Marilyn T.
AU - Winthrop, Kevin L.
AU - Gelfand, Joel M.
N1 - Funding Information: Funding sources: Supported in part by a grant ( P30AR069589-03 ) from the National Institutes of Health (to Dr Gelfand). Funding Information: Disclosure: Dr Syed is supported in part by a grant from Pfizer . Dr Shah is supported by a National Institutes of Health –funded T-32 postdoctoral fellowship. Dr Wan is supported in part by a grant from Pfizer . Dr Winthrop receives grants from Bristol Myers Squibb and Pfizer and is a consultant for UCB, AbbVie, Lilly, Bristol Myers Squibb, Pfizer, GlaxoSmithKline, and Roche. Dr Gelfand served as a consultant for Bristol Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (data safety and monitoring board), Sanofi, and Pfizer, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie , Janssen , Novartis , Sanofi , Celgene , Ortho Dermatologics , and Pfizer ; has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics ; is a copatent holder of resiquimod for treatment of cutaneous T-cell lymphoma; and is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Shin has no conflicts of interest to declare.
PY - 2021/1
Y1 - 2021/1
UR - http://www.scopus.com/inward/record.url?scp=85096168720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096168720&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2020.08.095
DO - 10.1016/j.jaad.2020.08.095
M3 - Article
C2 - 32860913
AN - SCOPUS:85096168720
VL - 84
SP - 161
EP - 163
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
SN - 0190-9622
IS - 1